HEPHAISTOS secures €10.3 M to reach the clinical stage

HEPHAISTOS-Pharma welcomes Elaia to complete its Seed Round, securing a total of €10.3 million from investors and non-dilutive financing.

• €4.5M seed round led by Elaia with xista sciences ventures, Fondation Fournier-Majoie, Noshaq, Angels Santé and Femmes Business Angels.

• €5.8M non-dilutive funding from the EIC accelerator, Bpifrance iNov, and France 2030 clinical grant.

• ONCO-Boost is a first-in-class immunostimulant targeting innate immune response to treat cancers non-responding to current regimens, including immunotherapies.

HEPHAISTOS-Pharma received from the MATWIN Board in 2020 the award for the « Best-In-Class therapeutic innovation » for their project OncoBOOST.